December 9, 2024

Life Harbor

Information regarding Healthcare

BMC Showcases Latest Sleep and Respiratory Healthcare Solutions at MEDICA 2024

BMC Showcases Latest Sleep and Respiratory Healthcare Solutions at MEDICA 2024
Classified in: Health
Subjects: PDT, TDS

DUSSELDORF, Germany, Nov. 16, 2024 /PRNewswire/ — BMC, a global developer of sleep and respiratory healthcare solutions encompassing Sleep Diagnostic, CPAP therapy, Data Management Platform solutions, and the CoughSync device, participated in the MEDICA 2024  exhibition at the Düsseldorf Exhibition Centre from November 11-14, 2024.

They showcased their latest advancements in sleep and respiratory care, including a global data management platform that enhances convenience for healthcare professionals (HCPs) and doctors in patient follow-up management.

Additionally, they introduced new product, the CoughSync device, which enables non-invasive clearance of airway secretions by simulating a natural cough in patients undergoing invasive ventilation.

During the exhibition, BMC’s team assembled to highlight its innovative PAP Link Digital Health Solution, specifically PAP Link Web, a cutting-edge cloud-based platform that boosts patient management, reporting, remote assistance, and supports healthcare professionals with medical insurance reimbursement, among other functionalities. Seamlessly connecting to BMC’s sleep, ventilation, and future healthcare devices, PAP Link Web empowers users to oversee patients across diverse treatment modalities.

Furthermore, the CoughSync 100EU device works in synchrony with the patient’s ventilator to suction sputum without interrupting ongoing ventilation.

“We’re collaborating closely with experts and doctors worldwide to co-create safer, more efficient, and smarter products,” said Lyla Niu, the Sales Director of BMC International Business Unit. “Through deep collaboration and exchanges, we’re propelling the industry towards a more prosperous and sustainable future. In China, we’ve established R&D centers in multiple cities, dedicated to product development and technological innovation. And in France, we’ve set up an office to better understand and cater to the needs of our European clientele.”

??Lyla Niu Sales Director | International Business Unit

BMC understands that focused and efficient patient data management is critical for clinicians. With over 20 years of experience, BMC’s innovative products and comprehensive solutions are designed to address these needs. These innovative, easy-to-use solutions provide advanced tools and technologies that drive impactful outcomes and create better sleep and respiratory health for people.

About BMC

BMC Medical Co., Ltd. (BMC), established in Beijing, China in 2001, was founded to partner with families worldwide in overcoming the discomfort of chronic respiratory diseases.

Photo –

These press releases may also interest you

at 22:41

On November 26, 2024, a group of Canadian doctors, nurses, and medical professionals, many of whom volunteered on medical missions to Gaza since October 2023, gather on Parliament Hill today to review how Israeli violence has systematically targeted…

at 20:30

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi…

at 19:27

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S….

at 19:23

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology…

at 19:00

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data from its Phase 1 trial of SCG101, a first-in-class…

at 14:05

Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the high-density microarray patch…

News published on and distributed by:

link

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.